Axogen, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Axogen completed its acquisition of BioCircuit Technologies, which developed NerveTape, the first FDA-cleared sutureless peripheral nerve repair device. BioCircuit is expected to contribute approximately $6 million to Q4 2026 revenue and approximately $34 million to full-year 2027 revenue. The acquisition price and other material terms are not disclosed in this press release.
Why this rating
Acquisition adds $40M annualized revenue (~9% of company scale) with strategic product fit, but integration risks and undisclosed purchase price limit certainty.
Price action (we called it positive)
before filing · preread $39.85 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.